The safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with inermediate or higer-risk myelodysplastic syndrome / 中华内科杂志
Chinese Journal of Internal Medicine
; (12): 908-910, 2019.
Article
en Zh
| WPRIM
| ID: wpr-799876
Biblioteca responsable:
WPRO
ABSTRACT
To retrospectively analyze the safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with intermediate or high-risk myelodysplastic syndrome (MDS). Three of the total 11 MDS patients achieved complete remission (CR) and 6 achieved hematological improvement (HI), 1 stable disease (SD), and 1 progressive disease (PD). One patient was treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). The median follow-up time was 413(90-1 275) d. Nine patients were still alive. Low dose subcutaneous decitabine combined with arsenic trioxide can be an alternative regimen for intermediate or high-risk MDS patients.
Texto completo:
1
Índice:
WPRIM
Tipo de estudio:
Etiology_studies
Idioma:
Zh
Revista:
Chinese Journal of Internal Medicine
Año:
2019
Tipo del documento:
Article